Dynport Vaccine Company LLC
UEI LXNEGTYDR755 · MD · subsidiary of Wico Limited · SAM.gov record ↗
$-3.7M
FY2025 obligations
11
Contract awards
Apr 30, 2006
First action
Mar 25, 2026
Latest action
Obligations by agency
- Department Of Defense$3.0M
- Department Of Health And Human Services$-6.7M
Obligations by NAICS
Monthly obligations
Oct 24
Nov 24
Dec 24
Jan 25
Feb 25
Apr 25
Jul 25
Sep 25
Nov 25
Dec 25
Jan 26
Mar 26
Contracts ending within 18 months (recompete watch)
| PIID | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|
| W911QY21C0093 ↗ | PERFORMANCE OF STABILITY TESTING ON RF1V DRUG PRODUCT (DP). | Department Of The Army | 541715 | $3.3M | Aug 5, 2021 | Aug 14, 2026 |
| 75N93022F00001 ↗ | TASK ORDER 75N93022F00001 BASE AWARD | National Institutes Of Health | 541715 | $435K | Jan 20, 2022 | Jan 12, 2027 |
| W911QY13C0056 ↗ | EXTEND DEADLINE FOR TERMINATION SETTLEMENT PROPOSAL SUBMISSION DATE TO 12 MARCH 2026 UNDER TERMINATED CONTRACT FOR FDA LICENSURE OF A BIOSCAVENGER PROPHYLAXIS. | Department Of The Army | 541711 | $-317K | May 8, 2013 | Mar 10, 2027 |
Largest awards
| PIID | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|
| W911QY21C0093 ↗ | PERFORMANCE OF STABILITY TESTING ON RF1V DRUG PRODUCT (DP). | Department Of The Army | 541715 | $3.3M | Aug 5, 2021 | Aug 14, 2026 |
| 75N93022F00001 ↗ | TASK ORDER 75N93022F00001 BASE AWARD | National Institutes Of Health | 541715 | $435K | Jan 20, 2022 | Jan 12, 2027 |
| 75N93021F00202 ↗ | PHASE 1 CLINICAL TRIAL UNIT FOR THERAPEUTICS AGAINST INFECTIOUS DISEASES | National Institutes Of Health | 541711 | $32K | May 12, 2021 | Jan 30, 2025 |
| 75N93025D00025 ↗ | "EVALUATION AND TESTING SERVICES (ETS) FOR VACCINES AND OTHER BIOLOGICS FOR INFECTIOUS DISEASES. | National Institutes Of Health | 541715 | $10K | Sep 29, 2025 | — |
| 0002 ↗ | TAFENOQUINE CLINICAL TRIALS | Defense Health Agency | 541712 | $6K | Mar 21, 2017 | Jul 30, 2022 |
| 75N93023F00001 ↗ | EPCTU | National Institutes Of Health | 541715 | $0 | May 14, 2023 | Jul 14, 2025 |
| 75N93022F00057 ↗ | PHASE I TASK AREA B -21-0013 - BASE | National Institutes Of Health | 541711 | $0 | Dec 13, 2021 | Dec 14, 2024 |
| 75N93022D00016 ↗ | EARLY PHASE CLINICAL TRIAL UNITS (EPCTU) | National Institutes Of Health | 541715 | $0 | Jan 13, 2022 | — |
| 75N93020F00001 ↗ | 1500005I DYNPORT VACCINE COMPANY | National Institutes Of Health | 541711 | $-352 | Dec 14, 2019 | Dec 13, 2020 |
| W911QY13C0056 ↗ | EXTEND DEADLINE FOR TERMINATION SETTLEMENT PROPOSAL SUBMISSION DATE TO 12 MARCH 2026 UNDER TERMINATED CONTRACT FOR FDA LICENSURE OF A BIOSCAVENGER PROPHYLAXIS. | Department Of The Army | 541711 | $-317K | May 8, 2013 | Mar 10, 2027 |
| HHSO100200600013C ↗ | CLOSE CONTRACT AND DEOBLIGATE EXCESS FUNDS | Office Of Assistant Secretary For Preparedness And Response | 325414 | $-7.2M | Apr 30, 2006 | Jan 29, 2012 |